Abstract: The present disclosure relates to a method for alleviating and/or treating a coronavirus disease in a subject in need thereof, including administering an effective amount of Ganoderma immunomodulatory protein, a recombinant thereof or a fragment thereof to the subject.

Abstract: The present technology relates to a method of analyzing a sample including an analyte. The method includes injecting the sample including the analyte into a mobile phase. The mobile phase includes a metal chelator additive having a concentration between about 1 ppm to about 10 ppm. The method also includes separating the analyte using liquid chromatography and analyzing the analyte using a mass spectrometer, an ultra-violet detector, or a combination thereof.

Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Abstract: Methods for producing a protein extract from cells, such as cells or cellular samples containing viral proteins, are provided. In general terms, the methods may involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent such as a polyoxyethylene alkyl ether, neutralizing the pH of the intermediate composition to produce the protein extract. Such methods can be used in conjunction with methods for detecting one or more target proteins in a sample, such as viral proteins. Systems, kits and compositions for practicing the subject methods are also provided.

Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Abstract: The present invention relates to methods for degrading or converting a cellulose-containing material, comprising: treating the cellulose-containing material with an effective amount of a cellulolytic enzyme composition comprising a polypeptide having cellulolytic enhancing activity, and one or more (several) components selected from the group consisting of a CEL7 polypeptide having endoglucanase activity, a CEL12 polypeptide having endoglucanase activity, a CEL45 polypeptide having endoglucanase activity, a CEL7 polypeptide having cellobiohydrolase activity with a cellulose binding domain, and a CEL7 polypeptide having cellobiohydrolase activity without a cellulose binding domain. The present invention also relates to such cellulolytic enzyme compositions.

Abstract: The present invention relates to a method of increasing resistance against fungal pathogens of the family Phacosporaceae plants and/or plant cells. This is achieved for instance by increasing the expression of a hydrophobin protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells. In the transgenic plants hydrophobin can be expressed as a fusion protein to facilitate and/or enhance expression. Furthermore, the hydrophobin protein can be expressed including a secretion signal sequence which mediates secretion of the protein into the apoplast and/or into the cuticule.

Abstract: The present invention relates to a solid support having a heat-resistant biotin-binding protein attached thereto. The present invention also relates to the use of the solid support of the present invention having a heat-resistant biotin-binding protein attached thereto. The present invention further relates to technical fields such as purification, concentration, detection and/or capture of a biotin-linked substance by means of a heat-resistant biotin-binding protein. Such a biotin-binding protein used in the solid support of the present invention is heat-resistant and is therefore useful for use in assay systems involving exposure to a temperature of 70° C. or more.

Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Abstract: Disclosed are: transcription regulatory factors capable of regulating the transcription or expression of genes for mannanases or cellulases, as mentioned below; and others. Specifically disclosed is a protein selected from the following proteins (a), (b) and (c): (a) a protein comprising the amino acid sequence depicted in SEQ ID NO:2; (b) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues (e.g., 1 to 5 amino acid residues) in the amino acid sequence depicted in SEQ ID NO:2 and which is capable of regulating the transcription of genes for mannanases or cellulases; and (c) a protein which comprises an amino acid sequence having a 70% or higher sequence identity to the amino acid sequence depicted in SEQ ID NO:2 and which is capable of regulating the transcription of genes for mannanases or cellulases, or a partial fragment of the protein. Also specifically disclosed are a gene encoding the protein, and others.

Abstract: The present invention relates to a glucose-induced inactivation/degradation-resistant transporter gene and use thereof, and more particularly, to a brewing yeast having excellent assimilation of oligosaccharides (maltose, maltotriose, etc.), an alcoholic beverage prepared using the yeast, a method of producing the alcoholic beverage, etc. More specifically, the present invention relates to a glucose-induced inactivation/degradation-resistant transporter including Mal21p, mutant Mal31p, mutant Mal61p, mutant Mtt1p, mutant Agt1p, etc., a gene encoding the transporter, a method of producing an alcoholic beverage using thereof, and so on.

Abstract: An active ingredient derived from Torulaspora delbrueckii and the use thereof for improving and/or restoring the barrier function of the skin. Also, cosmetic compositions containing this active ingredient and a cosmetic care process for improving and/or restoring the barrier function of the skin.

Abstract: Methoxypolyethyleneglycol succinimidyl propionate modified recombinant ganoderma immunoregulatory protein, a preparing method and applications thereof are provided, including: the mPEG-SPA modified rLZ-8; the method for preparing the mPEG-SPA modified rLZ-8 comprising: feeding the rLZ-8 dimer and the mPEG-SPA with the molar ratio of 1:1˜1:6 into a 0.1M phosphate buffer with pH 5.0˜pH 8.0, and stirring by a magnetic stirrer at a room temperature for 1.0˜2.5 h, purifying the product for obtaining a modification product with a purity of 98%; and applications of the mPEG-SPA modified rLZ-8 in preparation of medicine for treating leukopenia due to chemotherapy. Advantages are as follows: the method for preparing the mPEG-SPA modified rLZ-8 is simple, and the product is identical; a half-life of the mPEG-SPA modified rLZ-8 is significantly longer than the half-life of unmodified rLZ-8 (illustrated in the FIG. 2); a minimum effective dosage and time for treating leucopenia are also improved.

Abstract: The present invention relates to isolated polypeptides having carboxypeptidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The subject of the present invention is a method of modifying proteinaceous toxins through the addition of an NLS motif. The resulting cytotoxin facilitates the selective elimination of proliferating cells, particularly tumour cells.

Abstract: The present invention provides modified tamabidin 2, which is a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2, an amino acid sequence having one or more amino acid mutations in the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having an identity of not less than 80% to the amino acid sequence of SEQ ID NO: 2 and having biotin-binding activity, wherein an asparagine residue at position 115 of SEQ ID NO: 2 is replaced with cysteine. The modified biotin-binding protein has remarkable heat resistance.

Abstract: The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same.

Abstract: A novel method to produce hydrophobin monomers or multimers in plant tissues is disclosed. A novel method to produce hydrophobin multimers in E. coli cells is also described. The disclosure provides transgenic plants, transgenic seeds, a production system, and expression cassettes for making the transgenic plant carrying hydrophobin encoding gene sequences.

Abstract: The saccharification efficiency of cellulase is enhanced within reaction temperature regions of general fermenting microorganisms other than heat-resistant yeast. Cellulosic biomass is saccharified with cellulase in the presence of a polypeptide comprising the amino acid sequence shown in SEQ ID NO: 2 or 4 and having a function of enhancing the saccharifying activity of cellulase.

Abstract: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.

Abstract: The present disclosure relates to a novel ascomyceteous fungus, Sphaerodes mycoparasitica, for controlling plant fungal pathogens, disease symptoms, and mycotoxins in planta and ex planta. Uses, methods, compositions, sequences, and products are also disclosed herein.

Abstract: Disclosed are: transcription regulatory factors capable of regulating the transcription or expression of genes for mannanases or cellulases, as mentioned below; and others. Specifically disclosed is a protein selected from the following proteins (a), (b) and (c): (a) a protein comprising the amino acid sequence depicted in SEQ ID NO:2; (b) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues (e.g., 1 to 5 amino acid residues) in the amino acid sequence depicted in SEQ ID NO:2 and which is capable of regulating the transcription of genes for mannanases or cellulases; and (c) a protein which comprises an amino acid sequence having a 70% or higher sequence identity to the amino acid sequence depicted in SEQ ID NO:2 and which is capable of regulating the transcription of genes for mannanases or cellulases, or a partial fragment of the protein. Also specifically disclosed are a gene encoding the protein, and others.

Abstract: An objective to be achieved by the present invention is to provide a method for producing a heat processed food which can be uniformly heated in a short time without causing “unevenness of heating” on microwave oven cooking. Another objective of the present invention is also to provide a heat professed food, use of an antifreeze protein in producing a heat processed food, a method for improving an effect of heating treatment on a heat professed food, and an agent for improving an effect of heating treatment. The method for producing a heat processed food according to the present invention is characterized in comprising the steps of adding an antifreeze protein to a food material or a food; and cooling the resulting mixture.

Abstract: We describe an Fve polypeptide being a fragment, homologue, variant or derivative of Fve protein, which comprises at least one biological activity of Fve protein. uses of such a polypeptide, etc, and nucleic acids encoding these, in the treatment and prevention of allergy and cancer are also disclosed.

Abstract: The present invention relates to a modified biotin-binding protein. The modified biotin-binding protein of the present invention includes an amino acid sequence represented by SEQ ID NO: 2, an amino acid sequence having one to several amino acid mutations in the sequence represented by SEQ ID NO: 2, or an amino acid sequence having 80% or more identity to the sequence represented by SEQ ID NO: 2, and having a biotin-binding activity, wherein at least one residue selected from the group consisting of: 1) an arginine residue at position 104 of SEQ ID NO: 2; 2) a lysine residue at position 141 of SEQ ID NO: 2; 3) a lysine residue at position 26 of SEQ ID NO: 2; and 4) a lysine residue at position 73 of SEQ ID NO: 2 is replaced with an acidic amino acid residue or a neutral amino acid residue.

Abstract: This invention relates generally to a method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content as compared to a corresponding non-transformed wild type cell.

Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y-L-Z- radical wherein Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for the preparation of these compounds in a combinatorial manner, is also disclosed.

Abstract: This invention relates generally to nucleic acid sequences encoding proteins that are associated with abiotic stress responses and abiotic stress tolerance in plants. In particular, this invention relates to nucleic acid sequences encoding proteins that confer drought, heat, cold, and/or salt tolerance to plants.

Abstract: Disclosed is a novel lectin which can bind specifically to an L-fucose ?1?6 sugar chain. Also disclosed is use of the lectin. The L-fucose ?1?6 specific lectin of the present invention is characterized in that: (1) the lectin is extracted from a basidiomycete or an ascomycete; (2) the lectin has a molecular weight by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 4,000 to 40,000; and (3) the lectin has an affinity to an L-fucose ?1?6 sugar chain, the affinity being represented by an association constant of 1.0×104M?1 or more (at 25 degrees C.). The lectin can be used for detecting an L-fucose ?1?6 sugar chain specifically, and is effective for the purification of an L-fucose ?1?6 sugar chain or a non L-fucose ?1?6 sugar chain.

Abstract: This document relates to methods and materials involved in fungus-induced inflammation and eosinophil degranulation. For example, isolated nucleic acids encoding fungal polypeptides, fungal polypeptides, methods for assessing fungus-induced inflammation, methods for assessing eosinophil degranulation, and methods for identifying inhibitors of fungus-induced inflammation and/or eosinophil degranulation are provided.

Abstract: Fusion proteins comprising a transferrin moiety and integrin binding domain and peptide libraries thereof are disclosed. The present invention includes a method of screening transferrin and integrin peptide libraries displayed in fusion proteins expressed by host cells. The fusion proteins of the present invention include transferrin fusion proteins capable of expression in yeast.

Abstract: The present invention provides a pharmaceutical agent that is useful for preventing periodontal disease. The pharmaceutical agent contains a compound in which a mucin-type sugar chain-binding lectin is bound to a polypeptide having an integrin recognition sequence.

Abstract: The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: The present invention relates to a glucose-induced inactivation/degradation resistant transporter gene and use thereof, and more particularly to a brewery yeast having excellent assimilability of oligosaccharides (maltose, maltotriose, etc.), an alcoholic beverage produced using the yeast, and so on. In particular, the present invention relates to a glucose-induced inactivation/degradation resistant transporter such as Mal21p, etc., a gene encoding the same, a method of producing an alcoholic beverage using the same; and so on.

Abstract: N-deoxyribosyl transferases of Lactobacillus fermentum and their analogues, as well their use for the enzymatic synthesis of 2?,3?-dideoxynucleosides and 2?,3?-didehydro-2?,3?-dideoxynucleosides. These transferases and their analogues include a N-deoxyribosyl transferase protein (DTP) that has at least 70%-95% identity with the polypeptide of SEQ ID NO: 2 or SEQ ID NO: 4, that retains residues Y13, D77, D97, E103, and M312 which respectively correspond to positions 13, 77, 97, 103, and 132 of SEQ ID NO: 2; and that has threonine at a position corresponding to position 15 of SEQ ID NO: 2 or SEQ ID NO: 4. Polynucleotides, vectors and host cells encoding these N-deoxyribosyl transferases and their analogues.

Abstract: The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptide toxins and toxin production in mushrooms. In particular, the present invention relates to using genes and proteins from Amanita species encoding Amanita peptides, specifically relating to amatoxins and phallotoxins. In a preferred embodiment, the present invention also relates to methods for detecting Amanita peptide toxin genes for identifying Amanita peptide-producing mushrooms and for diagnosing suspected cases of mushroom poisoning. Further, the present inventions relate to providing kits for diagnosing and monitoring suspected cases of mushroom poisoning in patients.

Abstract: An immunomodulatory protein is cloned from Ganoderma microsporum. Its molecular weight is 15863.79 Da. Its genome sequence and translated protein sequence are different from those protected by the known patent of glycoprotein LZ-8, which is isolated from the mycelium of G. lucidum and has immunomodulator effect, and its immunomodulator efficiency is better than that of LZ-8.

Abstract: An object of the present invention are to provide a protease that is stable in a wide pH range from acidic to alkaline, and that has excellent thrombolytic activity; a protease-producing microorganism that produces the above protease; and a process for producing the protease. By culturing a novel filamentous fungus belonging to the genus Fusarium (Fusarium sp. strain BLB), a protease that is stable in a wide pH range from acidic to alkaline and that has excellent thrombolytic activity, is formed and accumulated in the culture medium, and recovered.

Abstract: The present invention provides a modified Saccharomyces yeast which produces significantly lower levels of ethanol than wild-type yeast under aerobic conditions and saccharide concentrations of 2% glucose, and which exhibits a growth rate of at least 30% of the wild-type yeast, preferably containing a chimeric construct of at least 2 saccharide transporters, nucleic acid molecules encoding the chimeras and polypeptides encoded by such sequences, and methods of using the modified yeast for preparing products in the yeast.

Abstract: The present invention provides a method for producing modified stable polypeptides introducing at least one non-natural amino acid into the hydrophobic region of the polypeptide. The thermal and chemical stability of such polypeptides is improved compared to those properties of its corresponding wild type proteins. The invention further provides purified leucine zipper and coiled-coil proteins in which the leucine residues have been replaced with 5,5,5-trifluoroleucines, and the modified proteins so produced demonstrate increased thermal and chemical stability compared to their corresponding wild-type natural proteins.

Abstract: The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular weight of about 7 kDa is identified as MAFP1 by N-terminal protein sequencing and comparative analysis. The purified MAFP1 protein can inhibit the growth of pathogens such as Paecilomyces variotii BCRC 33174 and Helminthosporium panici BCRC 35004. In addition, it is found by PCR test that the gene of this antifungal protein exists in other Monascus species such as M. Barkeri, M. floridanus, M. lunisporas, M. pilosus, M. ruber and the like. It is also been proved that the mafp1 gene and cDNA thereof in four Monascus strains, M. pilosus (BCRC 38072, BCRC 38093 and BCRC 31502) and M. ruber BCRC 31533, have the same DNA sequences.

Abstract: The present invention relates to the field of antibiotics, and more specifically to the isolation of nucleic acid molecules that code for the biosynthetic pathway of the glycopeptide antibiotic A40926. Disclosed are the functions of the gene products involved in A40926 production. The present invention provides biosynthetic genes that code for A40926 production, the encoded polypeptides, the recombinant vectors comprising the nucleic acid sequences that encode said polypeptides, the host cells transformed with said vectors and methods for producing glycopeptide antibiotics using said transformed host cells, including methods for producing A40926, a precursor thereof, a derivative thereof or a modified glycopeptide different from A 40926 or a precursor thereof.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.

Abstract: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the present invention, there can be provided an isolated and purified antigenic protein having high purity from Malassezia, antigenic fragments thereof, and a specific antibody against those antigenic protein or fragments thereof. In addition, there can be provided a diagnostic agent, a therapeutic agent, or a prophylactic drug for Malassezia allergoses, wherein the agent includes, as an active ingredient, the antigenic protein or fragments thereof.

Abstract: According to the present invention, there is provided a novel carbonyl reductase derived from a microbial belonging to the genus Ogataea and a DNA encoding the enzyme. By reducing ketones with the use of the carbonyl reductase, optically active alcohols, in particular, (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid esters can be produced. The carbonyl reductase according to the present invention is excellent in activity and stereoselectivity. Thus, according to the present invention, there is provided a process for producing optically active alcohols, which are industrially useful as intermediate materials for drugs, pesticides, etc.

Abstract: The present invention provides non-single-chain antigen-binding units that is stabilized by leucine zipper sequences. The experimental design is particularly useful for generating and screening for Nsc Abus that remain the binding capabilities to their respective antigens within a cell. The present invention also provides recombinant polynucleotides, host cells and kits comprising the vectors. Further provided by the invention are methods of using the subject vectors.

Abstract: A library of macrocyclic compounds of the formula (I) where part (A) is a ?bivalent radical, a —(CH2)y— bivalent radical or a covalent bond; where part (B) is a ?bivalent radical, a —(CH2)z— bivalent radical, or a covalent bond; where part (C) is a ?bivalent radical, a —(CH2)t— bivalent radical, or a covalent bond; and where part (T) is a —Y—L—Z— radical wherein number Y is CH2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assay or as intermediates for the synthesis of other compound of pharmaceutical interest. A process for their preparation of these compounds in a combinatorial manner, is also disclosed.

Abstract: The invention relates to an orotidine-5?-phosphate decarboxylase gene having the sequence of SEQ ID NO: 1 or its homologs, to a gene construct comprising this gene or its homologs, and to its use. The invention additionally relates to vectors or organisms comprising an orotidine-5?-phosphate decarboxylases gene having the sequence SEQ ID NO: 1 or its homologs. The invention further relates to a process for producing uracil-auxotrophic microorganisms and to a process for inserting DNA into uracil-auxotrophic microorganisms.